Capricor Therapeutics Inc Stock
A loss of -1.480% shows a downward development for Capricor Therapeutics Inc.
Our community identified positive and negative aspects for Capricor Therapeutics Inc stock for the coming years. 0 users see the criterium "Return on equity" as a plus for the Capricor Therapeutics Inc stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | -1.480% | -2.273% | 21.034% | 71.129% | -7.797% | 457.389% | 359.223% |
| Heron Therapeutics Inc. | 1.690% | -0.394% | -16.308% | -48.810% | -9.246% | -53.878% | -93.267% |
| Evolus Inc | -1.580% | 1.081% | -8.333% | -72.090% | -31.376% | -54.110% | -59.268% |
| Sangamo Therapeutics Inc. | -2.930% | 14.215% | 18.433% | -60.100% | 5.432% | -86.712% | -96.126% |
News
Here's Why This Biotechnology Skyrocketed by 439% in December
Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of
